Alnylam Pharmaceuticals ((ALNY)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: Alnylam Pharmaceuticals is conducting a study titled ‘Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program.’ The study aims to collect and evaluate pregnancy outcomes, complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP. This research is significant as it seeks to understand the safety and effects of patisiran-LNP during pregnancy.
Intervention/Treatment: The intervention being tested is Patisiran, a lipid nanoparticle (LNP) formulation known commercially as ONPATTRO. It is used to treat hereditary transthyretin-mediated amyloidosis and is now being monitored for its effects on pregnant women exposed to it.
Study Design: This is an observational cohort study with a prospective time perspective. It involves monitoring pregnant women who have been exposed to patisiran-LNP, without any specific allocation or intervention model, focusing on real-world outcomes.
Study Timeline: The study began on August 1, 2020. The primary completion and estimated completion dates are not specified, but the last update was submitted on July 15, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
Market Implications: This study update could influence Alnylam Pharmaceuticals’ stock performance by providing insights into the safety of patisiran-LNP during pregnancy, potentially impacting investor sentiment. As the study progresses, it may also affect the competitive landscape in the biopharmaceutical industry, particularly for companies developing similar treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.